Menu
/REGISTER
Montecito
Nixon Peabody
Chase
Bank of America
Loading...
You are here:  Home  >  Central Coast Health Watch  -  Page 84

Sansum Clinic
Latest

Amgen seeks European OK of biosimilar drug, partners with Merck on studies

By   /  Friday, December 4th, 2015  /  Central Coast Health Watch, East Ventura County, Latest news, Tri-County Public Companies  /  Comments Off on Amgen seeks European OK of biosimilar drug, partners with Merck on studies

Amgen announced two developments Dec. 4 that should help the Thousand Oaks-based biotech giant compete. Amgen said it is seeking approval from the European Medicines Agency for ABP 501, a biosimilar drug similar to Humira. Amgen also announced a partnership with New Jersey-based pharmaceutical Merck to partner in a non-Hodgkins lymphoma study using drugs from Read More →

Read More →
Latest

Amgen bipolar about biosimilars

By   /  Friday, December 4th, 2015  /  Central Coast Health Watch, Latest news, Top Stories, Tri-County Public Companies  /  Comments Off on Amgen bipolar about biosimilars

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Diabetes drug may be game changer

By   /  Friday, November 27th, 2015  /  Central Coast Health Watch, Latest news, Top Stories  /  Comments Off on Diabetes drug may be game changer

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen asks FDA to approve biosimilar drug

By   /  Wednesday, November 25th, 2015  /  Central Coast Health Watch, Latest news, Top Stories  /  Comments Off on Amgen asks FDA to approve biosimilar drug

Amgen submitted an application to the Food and Drug Administration for approval of its biosimilar drug ABP 501 on Nov. 25. ABP 501 is designed as a lower-cost version of Humira, which is approved to treat nine conditions including arthritis, skin disorders and colon inflammation. Humira, made by Chicago-based AbbVie, typically costs $20,000 per year Read More →

Read More →
Latest

Sientra collapse doomed execs

By   /  Friday, November 20th, 2015  /  Central Coast Health Watch, Latest news, Top Stories, Tri-County Public Companies  /  Comments Off on Sientra collapse doomed execs

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Dignity Health investment in Central Coast paying off

By   /  Friday, November 20th, 2015  /  Central Coast Health Watch, Columns, Latest news  /  Comments Off on Dignity Health investment in Central Coast paying off

During the past five years, Dignity Health has made methodical moves to bolster the healthcare system in North Santa Barbara and San Luis Obispo counties. That strategy has paid off in improved patient care and better facilities. Now health care is emerging as an industry that attracts talent and capital. It’s an industry that has Read More →

Read More →
Latest

Corporate social responsibility on hold when it comes to outrageous drug prices

By   /  Thursday, November 19th, 2015  /  Central Coast Health Watch, Op/Eds  /  Comments Off on Corporate social responsibility on hold when it comes to outrageous drug prices

Imagine you just went to your local pharmacy and were told that the cost of a life-saving drug was $22,500 for 30 tablets to treat AIDS or another infectious disease. Well, if you need the drug Daraprim, that is what you would have to pay. Turing Pharmaceuticals purchased the right to Darprim this past August Read More →

Read More →